logo
Plus   Neg
Share
Email

BD Reaffirms 2019 Outlook - Quick Facts

While reporting financial results for the third quarter, medical technology company Becton, Dickinson and Co. or BD (BDX) on Tuesday reaffirmed its adjusted earnings and revenue growth guidance for the full-year 2019.

For fiscal 2019, the company continues to project adjusted earnings in a range of $11.65 to $11.75 per share on revenue growth of 8.0 to 9.0 percent or 5.0 to 6.0 percent on a comparable, currency-neutral basis.

On average, analysts polled by Thomson Reuters expect the company to report earnings of $11.68 per share on revenue growth of 8.10 percent to $17.28 billion for the year. Analysts' estimates typically exclude special items.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The U.S. Food and Drug Administration approved an all-time record total of 1,171 generic drugs in fiscal 2019, breaking its previous record of 971 approvals in fiscal 2018. This year's approvals include 935 full approvals and 236 tentative approvals. A generic drug is a pharmaceutical drug that contains the same chemical substance and performs the same functions as a branded drug. Air Canada has extended its grounding of Boeing's 737 MAX-8 aircraft and removed it from its flying schedule until February 14, 2020. The airline had earlier said its fleet of 24 grounded jetliners will not join its schedules until January 8, 2020. The Canadian flag carrier said the extension is a result of the ongoing regulatory uncertainty about the timing of the aircraft returning to service. Google rolled out its Live Caption feature, which was first introduced at its I/O developer conference in May this year. The technology will automatically caption videos and spoken audio on a device, except for phone and video calls. It is helpful when a user is in a loud commuter train, or wants to follow along the conversation more closely.
Follow RTT
>